Novartis posted strong first-quarter results, aided ..... on the minor outperformance. Further, Novartis continues make strides with its pipeline ..... above the currently reported margins) as Novartis works to further optimize efficiencies.
growth (excluding currency changes) matched our expectations, as price increases and the inclusion of the acquired Novartis animal health group offset increased generic competition to neuroscience drugs Cymbalta and Zyprexa. During the quarter
* Q1 core operating income $3.65 bln vs poll average $3.30 bln
* On track for productivity gains of 3-4 percent of sales this year
ZURICH, April 23 (Reuters) - Swiss drugmaker Novartis on Thursday maintained its 2015 guidance as it posted first-quarter core net income that beat expectations.
operating in this market. Key Regions - Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc. - Valeant Pharmaceuticals International Inc. Other Prominent Vendors
April 20 (Reuters) - A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose
competitors became approved. While this increases the odds of higher sales and profits for Momenta (and its partner Novartis ), we still think the pending appeals court re-review of Copaxone's patents combined with Teva's ability to get
* Novartis : Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States Further company coverage: (Reporting By Zurich Slot)
* Novartis also picks top scientist to lead immuno-oncology (Adds details on Aduro's planned IPO, analyst comment)